Clinical Trials Directory

Trials / Unknown

UnknownNCT01141829

NADPH Oxidase Polymorphisms in Obstructive Sleep Apnea Syndrome (OSAS)

NADPH Oxidase p22phox Polymorphisms and Oxidative Stress in Patients With Obstructive Sleep Apnea

Status
Unknown
Phase
Study type
Observational
Enrollment
Sponsor
Sociedad Española de Neumología y Cirugía Torácica · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Obstructive Sleep Apnea (OSA) is associated with increased oxidative stress. The major sources of Reactive Oxygen Species (ROS) in the vasculature are the NADPH oxidases. Several polymorphisms related to NADPH oxidase expression or NADPH oxidase activity has been identified. The investigators are going to compare the distribution of the allelic frequencies of A-930G and C242T polymorphisms and their possible relationship with the levels of 8-isoprostanes as a marker of oxidative stress in patients with OSA and in a control group without OSA.

Detailed description

DESIGN: CASE-CONTROL STUDY METHODS: We are going to determine the A-930G and C242T p22phox genotypes in patients with OSA and healthy subjects recruited from sleep unit of Son Dureta University Hospital, (Palma de Mallorca, Spain). 8-Isoprostane is going to be measured as an oxidative stress marker with an 8-isoprostane EIA kit (Cayman Chemicals Company, USA) in plasma samples.

Conditions

Timeline

First posted
2010-06-11
Last updated
2010-06-11

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT01141829. Inclusion in this directory is not an endorsement.

NADPH Oxidase Polymorphisms in Obstructive Sleep Apnea Syndrome (OSAS) (NCT01141829) · Clinical Trials Directory